Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

ABCB1 c.2677G>T variation is associated with adverse reactions of OROS-methylphenidate in children and adolescents with ADHD.

Kim SW, Lee JH, Lee SH, Hong HJ, Lee MG, Yook KH.

J Clin Psychopharmacol. 2013 Aug;33(4):491-8. doi: 10.1097/JCP.0b013e3182905a8d.

PMID:
23771192
2.

Possible influence of variant of the P-glycoprotein gene (MDR1/ABCB1) on clinical response to guanfacine in children with pervasive developmental disorders and hyperactivity.

McCracken JT, Aman MG, McDougle CJ, Tierney E, Shiraga S, Whelan F, Arnold LE, Posey D, Ritz L, Vitiello B, Scahill L.

J Child Adolesc Psychopharmacol. 2010 Feb;20(1):1-5. doi: 10.1089/cap.2009.0059.

3.

Clinical pharmacogenetics in pediatric patients.

Husain A, Loehle JA, Hein DW.

Pharmacogenomics. 2007 Oct;8(10):1403-11. Review.

PMID:
17979513
4.

Interactions of attention-deficit/hyperactivity disorder therapeutic agents with the efflux transporter P-glycoprotein.

Zhu HJ, Wang JS, Donovan JL, Jiang Y, Gibson BB, DeVane CL, Markowitz JS.

Eur J Pharmacol. 2008 Jan 14;578(2-3):148-58. Epub 2007 Oct 5.

Supplemental Content

Loading ...
Support Center